A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases
Status:
NOT_YET_RECRUITING
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
This study looks at how well and safely SGB-9768 works for patients with certain kidney diseases: primary IgA nephropathy, C3 glomerulopathy, and immune complex-related membranoproliferative glomerulonephritis. It's a phase 2 trial done at several locations where both patients and doctors know what treatment is being given.